Quarterly ResultJul 30, 2026, 04:15 PM
Guardant Health Q2 Revenue +44% to $335M; Raises 2026 Guidance
AI Summary
Guardant Health reported strong second quarter 2026 financial results, with total revenue increasing 44% year-over-year to $335.0 million, driven by significant growth in both Oncology and Screening segments. The company raised its full year 2026 revenue guidance to a range of $1.34 billion to $1.36 billion, reflecting increased expectations for oncology and screening volumes. Key operational milestones included multiple FDA approvals for Guardant360 products and the inclusion of Shield in American Cancer Society guidelines, alongside new coverage from UnitedHealth Group.
Key Highlights
- Raised full year 2026 revenue guidance to $1.34 billion to $1.36 billion.
- Reported Q2 2026 total revenue of $335.0 million, an increase of 44% year-over-year.
- Q2 2026 Screening revenue grew over 250% to $52.9 million, with 66,000 Shield™ tests.
- Q2 2026 Oncology revenue increased 38% to $219.1 million, with 104,000 oncology tests.
- Received FDA approval for Guardant360® Liquid CDx and Guardant360® CDx as companion diagnostic.
- Shield included in American Cancer Society guidelines and obtained coverage from UnitedHealth Group.
- Q2 2026 non-GAAP gross margin was 67%, compared to 66% in the prior year period.
- Q2 2026 non-GAAP net loss was $(56.2) million, compared to $(55.0) million.
Price Impact
More from GH